

## Switching from NPH insulin to Gla-300 even more beneficial for older vs. younger patients


B. Wolnik, A. Hryniewiecki, D. Pisarczyk-Wiza, T. Szczepanik, and T. Klupa

Various studies have reported the benefits of **Gla-300** in patients with T2D

Do these same benefits apply to **older patients** switching from NPH insulin to Gla-300?

Improved glycemic control

Reduced risk of hypoglycemia







This multicenter observational study compared the safety and effectiveness of **switching from NPH insulin to Gla-300** in different subgroups of patients over 6 months



469 patients  
≥ 18 years  
HbA1c ≥ 8%

NPH insulin (≥ 6 months) → Gla-300



Aged ≤ 65 years



Aged > 65 years

≤ 13 years with T2D

> 13 years with T2D

Although the entire patient population with T2D benefits from switching from NPH to Gla-300, patients who are older than 65 or who have lived with T2D for more than 13 years **may benefit even more from switching to Gla-300 from NPH insulin** with regard to lower frequency of hypoglycemia

Gla-300, insulin glargine 300 U/mL; NPH, neutral protamine Hagedorn; T2D, type 2 diabetes